LINCOLN PHARMACEUTICALS
|
The Current P/E Ratio of LINCOLN PHARMACEUTICALS is 12.07.
| Share Price | ₹582.2 | Oct 01,2026 |
| Market Cap | ₹1,164.3 Cr | |
| Earnings-TTM | ₹96.5 Cr | TTM-Consolidated Results |
| Price/Earnings | 12.07x | Calculated as Market Cap/Earnings |
|---|---|---|
| Explore Stock Analytics | ||
Definition & Calculation of PE (Price/Earnings) ratio of LINCOLN PHARMACEUTICALS
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹1,164.3 Cr] as on Oct 01,2026
(/) Earnings [ ₹96.5 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ 12.07x ]
Thus, for LINCOLN PHARMACEUTICALS , the investors are currently willing to pay 12.07 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of LINCOLN PHARMACEUTICALS !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of LINCOLN PHARMACEUTICALS over the last five years.
Historical PE (Price/Earnings) ratio chart of LINCOLN PHARMACEUTICALS
PE Ratio Performance Analysis for LINCOLN PHARMACEUTICALS
- LINCOLN PHARMACEUTICALS 's p/e ratio for fiscal years ending Mar2026 to Mar2022 averaged 11.43x.
- LINCOLN PHARMACEUTICALS 's operated at median p/e ratio of 12.57x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, LINCOLN PHARMACEUTICALS 's p/e ratio peaked in Mar2025 at 13.42x.
- LINCOLN PHARMACEUTICALS 's p/e ratio hit its five-year low in Mar2022 of 8.98x.
How does LINCOLN PHARMACEUTICALS 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
| Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
|---|---|---|---|
| LINCOLN PHARMACEUTICALS | 96.45 | 12.07 | 1,164.3 |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 12,172.70 | 35.68 | 434,280.0 |
| DIVIS LABORATORIES LTD | 2,925.00 | 84.35 | 246,737.0 |
| TORRENT PHARMACEUTICALS LTD | 2,156.00 | 84.01 | 181,129.0 |
| CIPLA LTD | 3,364.84 | 32.34 | 108,808.0 |
| DR REDDYS LABORATORIES LTD | 3,169.30 | 31.61 | 100,170.0 |
| MANKIND PHARMA LTD | 2,055.11 | 50.79 | 104,376.0 |
| LUPIN LTD | 5,551.01 | 16.71 | 92,784.1 |
| ZYDUS LIFESCIENCES LTD | 4,492.20 | 25.43 | 114,239.0 |
| AUROBINDO PHARMA LTD | 3,712.74 | 25.96 | 96,375.8 |
| LAURUS LABS LTD | 1,090.76 | 98.53 | 107,468.0 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs LINCOLN PHARMACEUTICALS 's P/E Ratio
| Top 10 Industry Peers | PE Ratio |
|---|---|
| Min industry PE | 12.07x |
| Max industry PE | 98.53x |
| Median industry PE | 32.34x |
| Average industry PE | 45.22x |
You may also like the below Video Courses